HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Molecular Marvel       » Biogas beats Bioethanol       » Brain 'switch' can Turn off Drug Addiction (Eye on China)       » Novel Imaging Technology REFI takes Clinicians closer to detecting Stage 0 Tumour Lesions (Eye on China)      
INSIDE INDUSTRY
Scotland Demonstrates its Collaborative Approach to Cell Therapy Development
Scotland’s leading industry players, Sistemic and Roslin Cells, will be working together with Scottish Development International to make the process of undertaking clinical trials in cell therapy easier, faster and more successful in reaching commercial realization. By bringing together unique Scottish investments such as Health Sciences Scotland, NHS Research Scotland, NHS Scotland and leading technology-based industrial partners, the country believes it can offer cell therapy companies a streamlined process for clinical trials. This will not only provide access to the right patients, but will support product development, characterization and potency development, making the regulatory process much easier.

$120 million has been invested into the Scottish stem cell cluster since 2004 to build state of the art clinical infrastructure and fund essential projects for this industry, such as manufacturing GMP grade hESC. Its commercial landscape has developed some of the most promising advancements in enabling technologies that have helped guide cell functionality and have created viable cell therapy products fit for the clinic. Scotland was selected as the location to conduct the UK's first approved ATMP stem cell clinical trial and already has active cell therapies in clinical practice, which include a pancreatic islet transplantation programme for Type 1 Diabetes and EBV Cytotoxic T Lymphocyte (CTL) bank for post-transplant lympho-proliferative disease.

"Thanks to the outstanding collaboration across NHS, academia, government and industry, Roslin Cells has been able to accelerate the expansion of its cell therapy manufacturing facilities based in the Scottish Centre for Regenerative Medicine. We and our NHS partners are working on the development of a number of cellular therapies which will enter clinical trial within Scotland and Europe in the coming years. This pipeline of new therapies demonstrates the exceptional resources Scotland has to offer," Roslin Cells' CEO, Aidan Courtney said.

The supportive regulatory environment in Scotland including high ethical standards for stem cell research activities, has ensured cell therapy companies have a streamlined clinical research approach that ultimately enables new medicines to get to market faster.

"Understanding the cell therapy products being placed into trial as well as selecting the right patient population is essential to conducting a successful clinical trial. Sistemic's SistemQC™ technology is already helping some of the world's leading cell therapy companies to achieve this and it seems fitting that, as a company founded in Scotland, we work with Scottish Development International, NHS Scotland and other leading companies to make Scotland the go to place for conducting trials in cell therapy of the highest caliber," Sistemic's CEO Jim Reid explained.

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy